A leading investor consortium consisting of Nautic Partners, The Vistria Group and General Atlantic has signed a definitive agreement to acquire PANTHERx Rare from Centene Corporation (NYSE: CNC). The new partnership will focus on accelerating PANTHERx Rare's continued growth as a premier and trusted pharmacy care delivery model for patients living with rare and orphan diseases.
"PANTHERx transforms lives by providing access solutions to people living with rare medical conditions," said Jon Maschmeyer, Senior Partner and Co-Head of Healthcare at The Vistria Group. "Our investment was a collaborative effort to bring focus to an area that not only has been significantly underserved but also offers a wealth of opportunity to enhance the lives of patients."
"We see a growing market need for a specialized pharmacy model to support rare and orphan disease patients in their healthcare journey and to meet the unique distribution demands of these life-enriching medicines," said Justin Sunshine, Managing Director at General Atlantic.
The transaction is subject to clearance under the Hart-Scott Rodino Act and satisfaction of other customary closing conditions. Following the close of the transaction, the three consortium participants will each hold equal ownership of PANTHERx.